Prostate cancer: Mapping the course after CHAARTED


Until very recently, androgen deprivation therapy (ADT) has been the standard of care for men with metastatic hormonesensitive prostate cancer (mHSPC), with chemotherapy being reserved for men whose disease has progressed to castration resistance, in whom a survival benefit has been demonstrated.1,2 Often, clinicians and patients made the decision—supported… (More)
DOI: 10.1038/nrurol.2015.255


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics